NCT05798520: An ongoing trial by Biogen
This trial is ongoing. It must report results 10 months, 1 week from now.
Full data
| Full entry on ClinicalTrials.gov | NCT05798520 |
|---|---|
| Title | A 2-Part, Multicenter, Randomized, Blinded, Active-Controlled Phase 2 Study to Sequentially Evaluate the Safety and Efficacy of BIIB091 Monotherapy and BIIB091 Combination Therapy With Diroximel Fumarate in Participants With Relapsing Forms of Multiple Sclerosis |
| Results Status | Ongoing |
| ACT or pACT? | This is what FDAAA officially calls an "Applicable Clinical Trial" |
| Start date | July 25, 2023 |
| Completion date | Feb. 10, 2026 |
| Required reporting date | Feb. 10, 2027, midnight |
| Actual reporting date | None |
| Date last checked at ClinicalTrials.gov | March 26, 2026 |
| Days late | None |